Crossmark

Efficiency and safety of eltrombopag for multi-line failed Chinese patients with immune thrombocytopenia: cases with decreased megakaryocyte response well from single-center experience

Crossref DOI link: https://doi.org/10.1007/s12026-021-09245-w

Published Online: 2021-10-20

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Qi

Shen, Yingying

Li, Yuzhu

Hu, Huijin

Liu, Wenbin

Zhao, Yuechao

Dong, Huijie

Shen, Yiping

Zhou, Yuhong

Ye, Baodong

Wu, Dijiong https://orcid.org/0000-0003-2338-9365
Funding

Funding for this research was provided by:

national natural science foundation of china (82174138, 81603573)

zhejiang traditional chinese medicine administration (2020ZB085)

zhejiang outstanding young talent fund of traditional chinese medicine (2015ZQ012)
License Information

Text and Data Mining valid from 2021-10-20

Version of Record valid from 2021-10-20
More Information

Article History

Received: 19 July 2021

Accepted: 7 October 2021

First Online: 20 October 2021

Declarations

:

: This study was approved by the ethical committee of the First Affiliated Hospital of Zhejiang Chinese Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below